Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives

NCT07917364 is registered in ClinicalTrials.gov with University of Applied Sciences in Nowy Targ as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07917364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
Lead sponsor
University of Applied Sciences in Nowy Targ
Phase
Observational
Overall status
Recruiting
Start date
November 30, 2026
Completion date
March 31, 2027
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Metabolic Syndrome Group (MetS) Biomarker panel (asprosin, microRNA, BDNF, cortisol), Clinical and questionnaire assessment

    Women aged 18-35 years meeting NCEP ATP III criteria for metabolic syndrome (at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm), with no other comorbidity requiring continuous pharmacotherapy. Target n=55.

  • Control Group (CON) Biomarker panel (asprosin, microRNA, BDNF, cortisol), Clinical and questionnaire assessment

    Healthy women aged 18-35 years not meeting NCEP ATP III criteria for metabolic syndrome, matched for age, not receiving continuous pharmacotherapy. Target n=55.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Serum asprosin concentration At the single study visit (Day 1)

    Fasting serum asprosin concentration measured by enzyme-linked immunosorbent assay, compared between women with metabolic syndrome and healthy controls. Reported in ng/mL.

  • Expression of selected circulating microRNAs At the single study visit (Day 1)

    Relative expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) quantified in plasma by reverse-transcription quantitative PCR. Expression is normalized using ath-miR159a as an exogenous spike-in control and hsa-miR-186-5p as a reference. All six analytes are measured by the same method and reported in the same unit of measure, relative fold change, with results reported separately for each microRNA.

Similar trials

Same condition (Arachnodactyly) and phase, most recent start first.